Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder with an estimated prevalence of 1 in 250 people.1,2 This disorder is caused by pathogenic variants in the LDLR (OMIM 606945), APOB (OMIM 107730), and PCSK9 (OMIM 607786) genes that impair the clearance of low-density lipoproteins (LDLs) from the blood, leading to an increased risk of premature atherosclerotic cardiovascular disease (CVD).3,4,5,6 Despite its prevalence, FH remains underdiagnosed and undertreated.7 Here, PCSK9 is linked to familial hyperaldosteronism.